Metagenomi Technologies (MGX), which is developing precision genetic therapies, has filed for a proposed $100M initial public offering.
The biotech company didn’t specify terms in its SEC filing, but indicated that it was looking to raise $100M, a number that is likely a placeholder and subject to change.
Metagenomi hopes to list its shares on Nasdaq under the symbol MGX. Underwriters on the deal include JP Morgan, Jefferies, TD Cowen, Wells Fargo Securities, BMO Capital Markets and Chardan.
Based in Emeryville, Calif., Metagenomi is focused on developing curative therapies for genetic diseases such as hemophilia A and TTR using its proprietary genomic editing toolbox. The company’s drug candidates are still in the preclinical stage.